This article is more than 5 years old. Information may no longer be current.
Sunitinib effective in advanced sarcomatoid RCC
Click Here to Manage Email Alerts
Sunitinib appeared effective in patients with advanced sarcomatoid renal cell carcinoma, particularly those with a good performance status, according to results of a retrospective review.
Renal tumors with sarcomatoid differentiation are aggressive, poor-prognosis malignancies, and immunotherapy and chemotherapy often provide little benefit to these patients.
In the current study, researchers assessed OS, PFS and response rates in 23 patients with advanced sarcomatoid renal cell carcinoma treated with sunitinib (Sutent, Pfizer). The investigators also evaluated the impact of performance status, prognostic risk group and proportion of sarcomatoid component on outcomes.
Thirteen patients had a performance status of 0-1, and 10 patients had a performance status of 2-3.
Overall, median OS was 15.7 months (95% CI, 5.0-21.2) and median PFS was 5.7 months (95% CI, 3.2-12.6). Median survival was 20.9 months (95% CI, 9.7-63.3) among patients with a performance status of 0-1, compared with 5 months among patients with performance status of 2-3 (95% CI, 1.1-16.5).
The percentage of sarcomatoid component did not influence survival, according to the researchers.
Seven patients (30%) demonstrated objective response, five (22%) achieved stable disease and 11 (48%) experienced progressive disease. All of the patients who demonstrated objective response had a performance status of 0-1.
“Appropriate patient selection and risk-directed treatment remains essential in this aggressive disease,” the researchers concluded.
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.
Collapse
Click Here to Manage Email Alerts